Pfizer said its Q3 2025 revenues were $16,654 million ($17,702 million a year earlier, down 6%), with reported diluted EPS of $0.62 and adjusted diluted EPS of $0.87.

1. 01

   Pfizer said its Q3 2025 revenues were $16,654 million ($17,702 million a year earlier, down 6%), with reported diluted EPS of $0.62 and adjusted diluted EPS of $0.87.

2. 02

   Pfizer said it reaffirmed its full-year revenue guidance of $61.0 billion to $64.0 billion and raised and narrowed its adjusted diluted EPS guidance to $3.00 to $3.15 from the prior $2.90 to $3.10.

3. 03

   The company said it recorded a one-time $1.35 billion Acquired In-Process R&D charge in Q3 2025 related to an in-licensing agreement with 3SBio, Inc., with an unfavorable impact of approximately $0.20.

4. 04

   The company said it agreed to acquire Metsera for $47.50 in cash per share, representing an enterprise value of approximately $4.9 billion, and that holders may receive additional payments under a contingent value right (CVR) of up to $22.50 per share if milestones are met.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.